
Health Dictionary
Reliable, easy-to-read patient information on common medical conditions β written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Palmar plantar erythrodysesthesia pathophysiology
Introduction
Overview
Overview
The exact pathogenesis of palmar plantar erythrodysesthesia (PPE) is not completely understood. It is thought that PPE is caused by direct toxic effect of the chemotherapeutic drugs against keratinocytes, excretion of the drugs in eccrine sweat glands, or type I allergic reaction. The pathological features of PPE are non-specific. However, since PPE involves a cytotoxic reaction primarily affecting keratinocytes, the histopathologic findings are similar to histologic manifestation of direct toxic reactions.
Pathophysiology
Pathophysiology
Pathogenesis
- The exact pathogenesis of palmar plantar erythrodysesthesia (PPE) is not completely understood.
- Suggested explanations include:
- Direct toxic effect of the chemotherapeutic drugs against epidermal cells (keratinocytes).[1]
- Concentration and excretion of cytotoxic drugs in eccrine sweat glands causing damage or architectural insult.[2][3]
- Unique characteristics of the palms and the soles which justify their involvement as the preferred sites of involvement include: [2] [5] [6]
- High density of eccrine sweat glands[7]
- Absence of folliculo–sebaceous units (hair follicles and sebaceous glands)[7]
- Thick stratum corneum [7]
- Wide dermal papillae [7]
- High proliferation rate of epidermal basal cells
- The temperature and pressure gradient
- Gravitation forces
- Vascular anatomy peculiar to these areas
- In cases caused by capecitabine, higher expression of the capecitabine-activating enzyme thymidine phosphorylase in the skin of the palms[8]
Microscopic Pathology
Microscopic Pathology
- The pathological features of PPE are non-specific.
- However, since PPE involves a cytotoxic reaction primarily affecting keratinocytes, the histopathologic findings are similar to histologic manifestation of direct toxic reactions:
- Dominantly an interface dermatitis with a cell-poor infiltrate
- A variable degree of epidermal (keratinocytes) necrosis[9]
- Generally, in mild cytotoxic reactions (PPE WHO grades 1 and 2), necrosis is restricted to basal keratinocytes.
- In severe cytotoxic reactions (WHO grades 3 and 4) destruction of the entire basal layer occurs, and a blister along with complete epidermal necrosis may also be seen.[10]
- Other histologic manifestations in epidermis include:
- Vacuolar degeneration of the basal cell layer of epidermis
- Mild spongiosis
- Hyperkeratosis
- Lymphohistiocytic infiltrates
- Apoptosis of keratinocytes
- Partial separation of the epidermis from the dermis
- Dermal changes include:
- Superficial perivascular infiltration of dermis by lymphocytes and eosinophils
- Papillary dermal edema
- Neutrophilic eccrine hidradenitis
- Eccrine squamous syringometaplasia, in severe PPE (WHO grades 3 and 4)
- Histologic evidence of small-fiber neuropathy, as shown by reduced epidermal nerve fiber density, has been suggested to be responsible for occurrence of neuropathic pain, dysesthesias, paresthesias, and temperature intolerance in PPE. [11]
References
References
- β J. E. Fitzpatrick. “The cutaneous histopathology of chemotherapeutic reactions”. Journal of cutaneous pathology. PMIDΒ 8468414.
- β 2.0 2.1 Baack BR, Burgdorf WH (1991). “Chemotherapy-induced acral erythema”. J Am Acad Dermatol. 24 (3): 457β61. PMIDΒ 2061446.
- β Hiromi Tsuboi, Kohzoh Yonemoto & Kensei Katsuoka. “A case of bleomycin-induced acral erythema (AE) with eccrine squamous syringometaplasia (ESS) and summary of reports of AE with ESS in the literature”. The Journal of dermatology. PMIDΒ 16361756.
- β Perry, Michael (2012). Chemotherapy source book. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. ISBNΒ 9781451101454.
- β W. S. Susser, D. L. Whitaker-Worth & J. M. Grant-Kels. “Mucocutaneous reactions to chemotherapy”. Journal of the American Academy of Dermatology. PMIDΒ 10071309.
- β Yvonne Lassere & Paulo Hoff. “Management of hand-foot syndrome in patients treated with capecitabine (Xeloda)”. European journal of oncology nursingΒ : the official journal of European Oncology Nursing Society. doi:10.1016/j.ejon.2004.06.007. PMIDΒ 15341880.
- β 7.0 7.1 7.2 7.3 Cox GJ, Robertson DB (1986). “Toxic erythema of palms and soles associated with high-dose mercaptopurine chemotherapy”. Arch Dermatol. 122 (12): 1413β4. PMIDΒ 2947543.
- β Levine LE, Medenica MM, Lorincz AL, Soltani K, Raab B, Ma A (1985). “Distinctive acral erythema occurring during therapy for severe myelogenous leukemia”. Arch Dermatol. 121 (1): 102β4. PMIDΒ 3855356.
- β Fitzpatrick JE (1993). “The cutaneous histopathology of chemotherapeutic reactions”. J Cutan Pathol. 20 (1): 1β14. PMIDΒ 8468414.
- β Calista D, Landi C (1998). “Cytarabine-induced acral erythema: a localized form of toxic epidermal necrolysis?”. J Eur Acad Dermatol Venereol. 10 (3): 274β5. PMIDΒ 9643337.
- β Stubblefield MD, Custodio CM, Kaufmann P, Dickler MN (2006). “Small-Fiber Neuropathy Associated with Capecitabine (Xeloda)-induced Hand-foot Syndrome: A Case Report”. J Clin Neuromuscul Dis. 7 (3): 128β32. doi:10.1097/01.cnd.0000211401.19995.a2. PMIDΒ 19078798.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mandana Chitsazan, M.D. [2]
